Day: June 2, 2020

カナダ、オタワ, June 02, 2020 (GLOBE NEWSWIRE) — Teledyne Technologies（NYSE: TDY）の傘下で、産業用・研究用イメージング用途のデジタルカメラ製造・開発会社であるTeledyne Lumeneraは、新しいLtシリーズUSB3カメラを発表しました。堅牢でコンパクトな筐体とUSB3完全ロックコネクターを備えたこれらの新しいカメラは、24時間365日の稼働に耐える頑丈な構造になっています。さらに、Sony®製の最新のローリングシャッターStarvis™ CMOSセンサーとグローバルシャッターPregius™ CMOSセンサーを搭載し、2～20メガピクセルの解像度モデルをラインナップしています。、航空撮影、高度道路交通システム（ITS）、ロボットによる検査ソリューション、ライフサイエンスなどの多種多様なイメージング用途に威力を発揮します。Teledyne Lumenera Ltシリーズカメラは、小型、軽量、低コストを特徴とするイメージングソリューションを提供します。このソリューションは、省電力、省スペース、そして日増しに厳しくなる産業分野の予算といった要件を満たしながら、最新のビジョン性能を提供するという、今日のイメージングシステムの課題を満たすよう特別に設計されています。「新しいLtシリーズカメラは、今日のイメージング業界が求める機能すべてを一段と小型の形状で提供します」と、Teledyne LumeneraのゼネラルマネージャーであるGhislain Beaupréは述べ、次のように続けました。「これらのカメラにより、イメージングシステム設計者は、性能面でサイズ的な制約による不必要な妥協をすることなく、包括的な機能を有するカメラを搭載する新しい機会を得られます。」Teledyne Lumenera Ltシリーズカメラでは、Windows、Linux、組み込みシステムプラットフォーム用Linux、そしてシングルボードコンピューター（SBC）などの、32ビットおよび64ビットオペレーティングシステムと互換性があります。カメラは、産業用および科学分野の両方におけるイメージング用途として、ハイダイナミックレンジ、ハイスピードを低読み出しノイズで実現するように設計されています。主な機能：新しいUSB3カメラは、解像度2～12...

Denver, CO, June 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Helix Technologies, Inc. (OTCQB: HLIX) (the “Company”) announced today the release of Cannalytics Business Intelligence for cultivators, a groundbreaking data platform that delivers deep insights into the production end of the cannabis industry.  The platform is the industry’s first BI tool that integrates into cultivation software allowing growers to track and forecast yields, predict harvests, track yields on a strain by strain basis and maximize working capital availability through inventory management.  “Helix has quietly been on the leading edge of innovation in cannabis, in the same focused way we’ve continued to grow our market share and deliver new technology,” said Garvis Toler, Helix Technologies’ President of Data Services.  “Not only are we bringing...

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod in combination with Opdivo® (nivolumab) and Yervoy®* (ipilimumab) in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC) patients. Based on data to date, the Company plans to expand the study to further evaluate this triplet combination in MSS-CRC.To investigate the safety profile of this triplet combination, ILLUMINATE-206 was designed with a stepwise approach to Yervoy® dosage. Patients in this initial safety cohort of the study, many of whom were heavily pre-treated and rapidly progressing, received 8 mg of intratumoral tilsotolimod and 3 mg/kg...

Atlanta, June 02, 2020 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) will host a conference call on Tuesday, June 30, 2020, at 10:00 a.m. (EDT) to discuss the Company’s performance for the third quarter of fiscal 2020, following the announcement of those results earlier that day.  Neil M. Ashe, President and Chief Executive Officer of Acuity Brands, will lead the call.  A live Webcast of the discussion will be accessible at the Company’s Website:  www.acuitybrands.com.  A replay of the call will also be posted to that site within two hours of the completion of the conference call and will be archived on the site. About Acuity Brands  Acuity Brands, Inc. (NYSE: AYI) is a market-leading industrial technology company. We design, manufacture, and bring to market innovative products and services that make the world more brilliant,...

RICHLAND, Wash., June 02, 2020 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE American: ISR) today announced that the results of a new ten year study show positive outcomes for low-risk and intermediate-risk prostate cancer patients treated with Isoray’s Cesium-131 (Cesium Blu) internal radiation therapy (brachytherapy).Dr. Ronald Benoit, lead author of the study from the Department of Urology, University of Pittsburgh School of Medicine, addressed the findings, “As our data matures, our findings continue to demonstrate the excellent oncologic outcomes in men undergoing prostate brachytherapy with Cesium-131.” Speaking to the data on higher risk cancers, Dr. Benoit noted, “We do believe our long-term outcomes in men with high risk disease are somewhat underestimated in this manuscript due to a low number of patients at risk at ten years....

CALGARY, Alberta, June 02, 2020 (GLOBE NEWSWIRE) — ARROW Exploration Corp. (“Arrow” or the “Company”) (TSXV: AXL) is pleased to announce the filing of its 2019 year-end audited Financial Statements and MD&A, and the filing of its 2019 year-end reserve report, all of which are available on SEDAR (www.sedar.com).FINANCIAL AND OPERATING HIGHLIGHTS(1)Non-IFRS measures – see “Non-IFRS Measures” section within the MD&A(2)Long term restricted cash not included in working capitalMarshall Abbott, CEO of Arrow commented, “2019 represented the first full year of operations for Arrow as a new company. The Company made a significant commercial discovery in May 2019 on its Tapir Block, through successfully drilling the Rio Cravo Este-1 (RCE-1) well. We have identified two additional RCE well locations on the Tapir Block. On our LLA-23...

Articles of Association for A.P. Møller – Mærsk A/S stating adjusted share capital are hereby enclosed.AttachmentArticles of Association 23.03.2020

Hermed vedhæftes vedtægter for A.P. Møller – Mærsk A/S med angivelse af opdateret selskabskapital.Vedhæftet filVedtægter 23.03.2020

BASKING RIDGE, N.J., June 02, 2020 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will present an overview of CLBS119, Caladrius’ CD34+ cell therapy product candidate targeting repair of COVID-19 induced lung damage.For more information on BioNJ’s COVID-19 Rapid Fire Research Showcase, please click here.About Caladrius BiosciencesCaladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development...